Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine + Cyclophosphamide Followed by Zevalin in Relapsed/Refractory Non-Follicular Indolent Lymphomas
2005-000699-41Phase 2Terminated
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Feb 2007
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in Non-follicular indolent B-cell lymphoma (NF-iBCL), sponsored by Papa Giovanni XXIII Hospital. Started Feb 2007; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
Non-follicular indolent B-cell lymphoma (NF-iBCL)
Beyond the preview
Go deeper on 2005-000699-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000699-41.